Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 982-998

  Mudra, Daniel R ^a,b   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Active transport; Cytochrome P450; Inhibition; Intestinal absorption; Intestinal metabolism; Mass spectrometry; P glycoprotein; Passive diffusion transport; Permeability; Transcellular transport

Indexed keywords

ATENOLOL; CYTOCHROME P450 3A; GLYCOPROTEIN P; NORVERAPAMIL; VERAPAMIL;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE FUNCTION; INTESTINE MUCOSA; MALE; MODULATION; NONHUMAN; PERFUSION; PROTEIN TRANSPORT; RAT; TANDEM MASS SPECTROMETRY;

EID: 74049162816     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21912     Document Type: Article

References (49)

1. Pond SM, Tozer TN. 1984. First-pass elimination: Basic concepts and clinical consequences. Clin Pharmacokinet 9:1-25.
2. Kwan KC. 1997. Oral bioavailability and first-pass effects. Drug Metab Dispos 25:1329-1336.
3. Burton PS, Goodwin JT, Vidmar TJ, Amore BM. 2002. Predicting drug absorption: How nature made it a difficult problem. J Pharmacol Exp Ther 303:889-895.
4. Hochman JH, Fix JA, LeCluyse EL. 1994. In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine. JPET 269: 813-822.
5. Knipp GT, Ho NF, Barsuhn CL, Borchardt RT. 1997. Paracellular diffusion in Caco-2 cell monolayers: Effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 86:1332-1340.
6. Artursson P, Magnusson C. 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 79:595-600.
7. Madara JL. 1998. Regulation of the movement of solutes across tight junctions. Annu Rev Phsyiol 60:143-159.
8. Salama NN, Eddington ND, Fasano A. 2006. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58:15-28.
9. Kondoh M, Yagi K. 2007. Progress in absorption enhancers based on tight junction. Expert Opin Drug Deliv 4:275-286.
10. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455:152-162.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
12. Mouly S, Paine MF. 2003. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599.
13. Troutman MD, Luo G, Gan LS, Thakker DR. 2002. The role of P-glycoprotein in drug disposition: Significance to drug development. In: Rodrigues AD, editor. Drugs and the Pharmaceutical Sciences, Vol. 116: Drug-Drug Interactions. New York, New York: Marcel-Decker. pp 295-357.
14. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. 2003. P-glycoproteinmediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-231.
15. Johnson BM, Chen W, Borchardt RT, Charman WN, Porter CJH. 2003. A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. JPET 305:151-158.
16. Gramatte T, Oertel R. 1999. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239-245.
17. Back DJ, Madden S, Orme ML. 1990. Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol 163:2138-2145.
18. Arellano C, Philibert C, Vachoux C, Woodley J, Houin G. 2007. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: In vitro studies with everted gut sacs. J Pharm Pharm Sci 10:26-36.
19. Kunta JR, Lee SH, Perry BA, Lee Y-H, Sinko PJ. 2004. Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular accessed-ported (IVAP) rabbits. Drug Metab Dispos 32:1293-1298.
20. Ho NFH, Park JY, Morozowich W, Higuchi WI. 1977. Physical model approach to the design of drugs with improved intestinal absorption. In: Roche EB, editor. Design of biopharmaceutical properties through prodrugs and analogs. Washington DC: American Pharmaceutical Association, Academy of Pharmaceutical Sciences. pp 136-227.
21. Spahn-Langguth H, Langguth P. 1997. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J pharm Sci 12:361-367.
22. Conseil G, Baubichon-Cortay H, Dayan G, Jault J-M, Barron D, DiPietro A. 1998. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95:9831-9836.
23. Paine MF, Oberlies NH. 2007. Clinical relevance of the small intestine as an organ of drug elimination: Drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 3:67-80.
24. Marchbanks CR. 1993. Drug-drug interactions with fluroquinolones. Pharmacotherapy 13:23S-28S.
25. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. 2001. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:523-537.
26. Boger RH. 2001. Drug interactions of the statins and consequences for drug selection. Int J Clin Pharmcol Ther 39:369-382.
27. Lennernas H, Nylander S, Ungell A-L. 1997. Jejunal permeability: A comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm Res 14:667-671.
28. Tsutsumi K, Li K, Ghanem A-H, Ho NFH, Higuchi WI. 2003. A systematic examination of the in vitro Ussing chamber and the in situ single-pass perfusion model systems in rat ileum permeation of model solutes. J Pharm Sci 92:344-359.
29. Hidalgo IJ. 1996. Cultured intestinal epithelial cell models. In: Borchardt RT, Smith P, Wilson G, editors. Models for assessing drug absorption and metabolism. New York, New York: Plenum Press. pp 35-50.
30. Kavin H, Levin NW, Stanley MM. 1967. Isolated perfused rat small bowel - Technic, studies of viability, glucose absorption. J Appl Physiol 22:604-611.
31. Griffiths R, Lewis A, Jeffrey P. 1996. Models of drug absorption in situ and in conscious animals. In: Borchardt RT, Smith P, Wilson G, editors. Models for assessing drug absorption and metabolism. New York, New York: Plenum Press. pp 67-82.
32. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
33. McAllister RG, Tan TG. 1980. Effect of hypothermia and drug metabolism. Pharmacology 20:95-100.
34. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko P. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160-1167.
35. 3H]-verapamil radioligand-binding assay. JPET 288: 348-357.
36. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. JPET 299:620-628.
37. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quantitative evaluation of the function of small intestinal P-glycoprotein: Comparative studies between in situ and in vivo. Pharm Res 20:1163-1169.
38. Li S, Liu G, Jia J, Liu Y, Pan C, Yu C, Cai Y, Ren J. 2006. Simultaneous determination of ten antiarrythic drugs and a metabolite in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 847:174-181.
39. Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel KE. 1999. First-pass midazolam metabolism catalyzed by 1alpha 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 289:1134-1142.
40. Neuhoff S, Langguth P, Dressler C, Anderson TB, Regardh CG, Spahn-Langguth H. 2000. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 38:168-179.
41. Achira M, Suzuki H, Ito K, Sugiyama Y. 1999. Comparitave studies to determine selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm Sci 1:E18.
42. Cummins CL, Salphati L, Reid MJ, Benet LZ. 2003. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. JPET 305:306-314.
43. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RQ, Thakker DR. 1996. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin in Caco-2 cells. Drug Metab Dispos 24:344-349.
44. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. 2000. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A. JPET 292:310-318.
45. Benet LZ, Cummins CL,WuCY. 2003. Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398.
46. Knight B, Troutman M, Thakker DR. 2006. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: A major challenge. Curr Opin Pharmacol 6:528-532.
47. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. 2002. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 46:160-165.
48. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE. 2003. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20:757-764.
49. Hyafil F, Vergely C, DuVignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF-120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.